Healthcare Industry ITP Therapeutics Market Size 2020 | Page 4

Your Catalyst To a Lucrative Business
3.3.1 IVIG for ITP market, 2012 - 2020 (USD Million)
3.4 Anti-D Immunoglobulin
3.4.1 Anti-D for ITP market, 2012 - 2020 (USD Million)
3.4.1.1 Thrombopoietin receptor agonists (TPO-RA)
3.4.2 TPO-RA for ITP market, 2012 - 2020 (USD Million)
3.5 Others
3.5.1 Monoclonal antibody therapy (qualitative analysis)
3.5.2 Immunosuppressant therapy (qualitative analysis)
3.5.3 Cyclosporine (qualitative analysis)
3.5.4 Platelets clearance inhibitors (qualitative analysis)
3.5.5 Vinca alkaloids (qualitative analysis)
3.5.6 Stem cell transplantation (qualitative analysis)
3.5.7 Others therapies for ITP market, 2012 - 2020 (USD Million)
Chapter 4 ITP Regional Outlook
4.1 ITP therapeutics market share, by region, 2013 & 2020
4.2 North America
4.2.1 North America ITP therapeutics market, 2012 - 2020 (USD Million)
4.2.2 U.S.
4.2.3 Mexico ITP therapeutics market, by product, 2012 - 2020 (USD Million)
4.3 Europe
4.3.1 Europe ITP therapeutics market, 2012 - 2020 (USD Million)
4.3.2 Germany ITP therapeutics market, by product, 2012 - 2020 (USD Million)
4.3.3 UK ITP therapeutics market, by product, 2012 - 2020 (USD Million)
4.4 Asia Pacific
4.4.1 Asia Pacific ITP therapeutics market, 2012 - 2020 (USD Million)
4.4.2 India ITP therapeutics market, 2012 - 2020, by product
4.4.3 Japan ITP therapeutics market, product, 2012 - 2020 (USD Million)
4.4.4 China
4.5 RoW
4.5.1 Row ITP therapeutics market, 2012 - 2020 (USD Million)
4.5.2 Brazil ITP therapeutics market, by product, 2012 - 2020 (USD million)
Chapter 5 Competitive Landscape
5.1 Amgen.
5.1.1 Company Overview
5.1.2 Financial Performance
5.1.3 Product Benchmarking
5.1.4 Strategic Initiatives
5.2 F. Hoffman-La Roche AG
5.2.1 Company Overview
5.2.2 Financial Performance
5.2.3 Product Benchmarking
5.2.4 Strategic Initiatives
5.3 Grifols Biologicals Inc.
5.3.1 Company Overview
Follow Us: